AU2019269391B2 - MCL-1 inhibitors - Google Patents
MCL-1 inhibitors Download PDFInfo
- Publication number
- AU2019269391B2 AU2019269391B2 AU2019269391A AU2019269391A AU2019269391B2 AU 2019269391 B2 AU2019269391 B2 AU 2019269391B2 AU 2019269391 A AU2019269391 A AU 2019269391A AU 2019269391 A AU2019269391 A AU 2019269391A AU 2019269391 B2 AU2019269391 B2 AU 2019269391B2
- Authority
- AU
- Australia
- Prior art keywords
- formula
- compound
- pharmaceutically acceptable
- acceptable salt
- membered heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- GLIBHRPOVQJJOO-VIPLDISFSA-N CCC(N[S@@](CCCCC[C@@H]([C@H](CC1)[C@@H]1CN(C1)c(cc2cc3)c3OC[C@@]11c3ccccc3CCC1)OC)(=NC2=O)=O)=O Chemical compound CCC(N[S@@](CCCCC[C@@H]([C@H](CC1)[C@@H]1CN(C1)c(cc2cc3)c3OC[C@@]11c3ccccc3CCC1)OC)(=NC2=O)=O)=O GLIBHRPOVQJJOO-VIPLDISFSA-N 0.000 description 1
- SOOOBSWPZMQCEN-FNCGQFNISA-N CCNC(N[S@@](CCCCC[C@@H]([C@H](CC1)[C@@H]1CN(C1)c(cc2cc3)c3OC[C@@]1(CCC1)c(cc3)c1cc3Cl)OC)(=NC2=O)=O)=O Chemical compound CCNC(N[S@@](CCCCC[C@@H]([C@H](CC1)[C@@H]1CN(C1)c(cc2cc3)c3OC[C@@]1(CCC1)c(cc3)c1cc3Cl)OC)(=NC2=O)=O)=O SOOOBSWPZMQCEN-FNCGQFNISA-N 0.000 description 1
- SOOOBSWPZMQCEN-AZNMOJQZSA-N CCNC(N[S@](CCCCC[C@@H]([C@H](CC1)[C@@H]1CN(C1)c(cc2cc3)c3OC[C@@]1(CCCc1c3)c1ccc3Cl)OC)(=NC2=O)=O)=O Chemical compound CCNC(N[S@](CCCCC[C@@H]([C@H](CC1)[C@@H]1CN(C1)c(cc2cc3)c3OC[C@@]1(CCCc1c3)c1ccc3Cl)OC)(=NC2=O)=O)=O SOOOBSWPZMQCEN-AZNMOJQZSA-N 0.000 description 1
- TXGKGYNGNHIKID-AFWRSLRVSA-N CN(C)CCC(NS(CCC/C=C/[C@@H]([C@H](CC1)[C@@H]1CN(C1)c(cc2cc3)c3OC[C@@]1(CCC1)c(cc3)c1cc3Cl)OC)(=NC2=O)=O)=O Chemical compound CN(C)CCC(NS(CCC/C=C/[C@@H]([C@H](CC1)[C@@H]1CN(C1)c(cc2cc3)c3OC[C@@]1(CCC1)c(cc3)c1cc3Cl)OC)(=NC2=O)=O)=O TXGKGYNGNHIKID-AFWRSLRVSA-N 0.000 description 1
- ZXWAWTTVTTVJJY-UHFFFAOYSA-N COC(C(CC1)C1CN(C1)c2cc(C(N=3)=O)ccc2OCC1(CCC1)c(cc2)c1cc2[ClH]C)C=CCCCS=3=O Chemical compound COC(C(CC1)C1CN(C1)c2cc(C(N=3)=O)ccc2OCC1(CCC1)c(cc2)c1cc2[ClH]C)C=CCCCS=3=O ZXWAWTTVTTVJJY-UHFFFAOYSA-N 0.000 description 1
- QIAJPYCFRRHRHY-UHFFFAOYSA-N COC(CCCCCS(=NC(c(cc1)c2)=O)=O)C(CC3)C3CN3c2c1OCCCCc1ccccc1C3 Chemical compound COC(CCCCCS(=NC(c(cc1)c2)=O)=O)C(CC3)C3CN3c2c1OCCCCc1ccccc1C3 QIAJPYCFRRHRHY-UHFFFAOYSA-N 0.000 description 1
- QHHXGWUIPREVGT-UHFFFAOYSA-N COC(CCCCCS(=NC1=O)=O)C(CC2)C2CN(C2)c3cc1ccc3OCC2(CCCc1c2)c1ccc2Cl Chemical compound COC(CCCCCS(=NC1=O)=O)C(CC2)C2CN(C2)c3cc1ccc3OCC2(CCCc1c2)c1ccc2Cl QHHXGWUIPREVGT-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D267/20—[b, f]-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C381/00—Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
- C07C381/10—Compounds containing sulfur atoms doubly-bound to nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Hematology (AREA)
- Oncology (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021203373A AU2021203373B2 (en) | 2018-05-14 | 2021-05-25 | MCL-1 inhibitors |
| AU2023270332A AU2023270332B2 (en) | 2018-05-14 | 2023-11-24 | MCL-1 inhibitors |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862671306P | 2018-05-14 | 2018-05-14 | |
| US62/671,306 | 2018-05-14 | ||
| US201862749918P | 2018-10-24 | 2018-10-24 | |
| US62/749,918 | 2018-10-24 | ||
| PCT/US2019/032053 WO2019222112A1 (en) | 2018-05-14 | 2019-05-13 | Mcl-1 inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021203373A Division AU2021203373B2 (en) | 2018-05-14 | 2021-05-25 | MCL-1 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2019269391A1 AU2019269391A1 (en) | 2020-11-19 |
| AU2019269391B2 true AU2019269391B2 (en) | 2021-02-25 |
Family
ID=66770559
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019269391A Active AU2019269391B2 (en) | 2018-05-14 | 2019-05-13 | MCL-1 inhibitors |
| AU2021203373A Active AU2021203373B2 (en) | 2018-05-14 | 2021-05-25 | MCL-1 inhibitors |
| AU2023270332A Active AU2023270332B2 (en) | 2018-05-14 | 2023-11-24 | MCL-1 inhibitors |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021203373A Active AU2021203373B2 (en) | 2018-05-14 | 2021-05-25 | MCL-1 inhibitors |
| AU2023270332A Active AU2023270332B2 (en) | 2018-05-14 | 2023-11-24 | MCL-1 inhibitors |
Country Status (30)
| Country | Link |
|---|---|
| US (5) | US10703733B2 (enExample) |
| EP (2) | EP4029868A1 (enExample) |
| JP (3) | JP6899975B2 (enExample) |
| KR (4) | KR102666717B1 (enExample) |
| CN (2) | CN112118845B (enExample) |
| AU (3) | AU2019269391B2 (enExample) |
| BR (1) | BR112020021648A2 (enExample) |
| CA (1) | CA3099152C (enExample) |
| CL (1) | CL2020002919A1 (enExample) |
| CO (1) | CO2020014009A2 (enExample) |
| CR (1) | CR20200544A (enExample) |
| CY (1) | CY1125065T1 (enExample) |
| DK (1) | DK3793565T3 (enExample) |
| ES (1) | ES2907923T3 (enExample) |
| HR (1) | HRP20220215T1 (enExample) |
| HU (1) | HUE057852T2 (enExample) |
| IL (2) | IL291430B2 (enExample) |
| LT (1) | LT3793565T (enExample) |
| MX (1) | MX2020012137A (enExample) |
| MY (1) | MY198871A (enExample) |
| PE (1) | PE20210004A1 (enExample) |
| PH (1) | PH12020551881A1 (enExample) |
| PL (1) | PL3793565T3 (enExample) |
| PT (1) | PT3793565T (enExample) |
| SG (1) | SG11202010964VA (enExample) |
| SI (1) | SI3793565T1 (enExample) |
| TW (4) | TWI719478B (enExample) |
| UA (1) | UA125163C2 (enExample) |
| WO (1) | WO2019222112A1 (enExample) |
| ZA (1) | ZA202007007B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112118845B (zh) | 2018-05-14 | 2023-06-13 | 吉利德科学公司 | Mcl-1抑制剂 |
| EP3643711A1 (en) | 2018-10-24 | 2020-04-29 | Bayer Animal Health GmbH | New anthelmintic compounds |
| US20240067660A1 (en) | 2019-07-09 | 2024-02-29 | Janssen Pharmaceutica Nv | Macrocyclic spirocycle derivatives as mcl-1 inhibitors |
| EP4045083B1 (en) | 2019-10-18 | 2024-01-10 | Forty Seven, Inc. | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
| NZ786589A (en) | 2019-10-31 | 2025-03-28 | Forty Seven Llc | Anti-cd47 and anti-cd20 based treatment of blood cancer |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| AU2020391106B2 (en) | 2019-11-26 | 2024-03-21 | Gilead Sciences, Inc. | Processes and intermediates for preparing MCL1 inhibitors |
| CN117736207A (zh) | 2019-12-24 | 2024-03-22 | 卡尔那生物科学株式会社 | 二酰基甘油激酶调节化合物 |
| US20230212191A1 (en) * | 2020-04-16 | 2023-07-06 | Prelude Therapeutics, Incorporated | Spiro-sulfonimidamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein |
| CN115698023A (zh) * | 2020-06-10 | 2023-02-03 | 詹森药业有限公司 | 作为mcl-1抑制剂的大环2-氨基-3-氟-丁-3-烯酰胺 |
| US12202782B2 (en) * | 2020-11-19 | 2025-01-21 | Gilead Sciences, Inc. | Processes and intermediates for preparing MCL1 inhibitors |
| ES3026771T3 (en) | 2020-12-17 | 2025-06-12 | Janssen Pharmaceutica Nv | Macrocyclic branched 3-fluoro-but-3-enamides as inhibitors of mcl-1 |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| JP2024516641A (ja) | 2021-04-26 | 2024-04-16 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍｃｌ－１阻害剤としての大環状２－アリルテトラヒドロフラン |
| WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
| EP4351657A1 (en) * | 2021-06-11 | 2024-04-17 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-body drug conjugates |
| AU2022291381B2 (en) * | 2021-06-11 | 2025-04-24 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-cancer agents |
| CN117377671A (zh) | 2021-06-23 | 2024-01-09 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| CN117480155A (zh) | 2021-06-23 | 2024-01-30 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| JP7686091B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| EP4359415A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2023088894A1 (en) | 2021-11-16 | 2023-05-25 | Janssen Pharmaceutica Nv | Macrocyclic 2-amino-but-3-enamides as inhibitors of mcl-1 |
| AU2023240346A1 (en) | 2022-03-24 | 2024-09-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| KR20250004050A (ko) * | 2022-05-04 | 2025-01-07 | 길리애드 사이언시즈, 인코포레이티드 | 특정한 mcl-1 저해제의 염 및 다형체 |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016033486A1 (en) * | 2014-08-29 | 2016-03-03 | Amgen Inc. | Tetrahydronaphthalene derivatives that inhibit mcl-1 protein |
| WO2017147410A1 (en) * | 2016-02-25 | 2017-08-31 | Amgen Inc. | Compounds that inhibit mcl-1 protein |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6319494B1 (en) | 1990-12-14 | 2001-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| WO2005014599A1 (en) | 2003-06-04 | 2005-02-17 | Cellular Genomics, Inc. | Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds |
| RS55546B1 (sr) | 2004-05-13 | 2017-05-31 | Icos Corp | Hinazolinoni kao inhibitori humane fosfatidilonozitol 3-delta kinaze |
| US20090142345A1 (en) | 2005-03-15 | 2009-06-04 | Takeda Pharmaceutical Company Limited | Prophylactic/therapeutic agent for cancer |
| EP2418278A3 (en) | 2005-05-09 | 2012-07-04 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| KR101607288B1 (ko) | 2005-07-01 | 2016-04-05 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| CN101861313B (zh) | 2007-03-12 | 2014-06-04 | Ym生物科学澳大利亚私人有限公司 | 苯基氨基嘧啶化合物及其用途 |
| WO2009017833A2 (en) | 2007-08-02 | 2009-02-05 | Arresto Biosciences | Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis |
| EP2310509B1 (en) | 2008-07-21 | 2015-01-21 | Apogenix GmbH | Tnfsf single chain molecules |
| US8652843B2 (en) | 2008-08-12 | 2014-02-18 | Oncomed Pharmaceuticals, Inc. | DDR1-binding agents and methods of use thereof |
| US8450321B2 (en) | 2008-12-08 | 2013-05-28 | Gilead Connecticut, Inc. | 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor |
| TWI625121B (zh) | 2009-07-13 | 2018-06-01 | 基利科學股份有限公司 | 調節細胞凋亡信號之激酶的抑制劑 |
| EP2531217A4 (en) | 2010-02-04 | 2013-11-27 | Gilead Biologics Inc | ANTIBODIES THAT BIND TO LOXL2 (LYSYL OXIDASE-LIKE 2) AND METHODS OF USE THEREOF |
| WO2011146862A1 (en) | 2010-05-21 | 2011-11-24 | Bellicum Pharmaceuticals, Inc. | Methods for inducing selective apoptosis |
| KR101827048B1 (ko) | 2010-08-27 | 2018-02-07 | 길리아드 바이오로직스, 인크. | 매트릭스 메탈로프로테이나제 ９에 대한 항체 |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| TWI567061B (zh) | 2011-07-01 | 2017-01-21 | 吉李德科學股份有限公司 | 用於治療成癮之化合物 |
| EP2749572A4 (en) | 2011-08-23 | 2015-04-01 | Chugai Pharmaceutical Co Ltd | NEW ANTI-DDR1 ANTIBODY WITH ANTITUMORACTIVITY |
| GB201115529D0 (en) | 2011-09-08 | 2011-10-26 | Imp Innovations Ltd | Antibodies, uses and methods |
| WO2013052699A2 (en) | 2011-10-04 | 2013-04-11 | Gilead Calistoga Llc | Novel quinoxaline inhibitors of pi3k |
| UY34573A (es) | 2012-01-27 | 2013-06-28 | Gilead Sciences Inc | Inhibidor de la quinasa que regula la señal de la apoptosis |
| WO2013116562A1 (en) | 2012-02-03 | 2013-08-08 | Gilead Calistoga Llc | Compositions and methods of treating a disease with (s)-4 amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile |
| AR092662A1 (es) | 2012-09-24 | 2015-04-29 | Gilead Sciences Inc | Anticuerpos anti-ddr1 |
| JP6125663B2 (ja) | 2012-12-21 | 2017-05-10 | ギリアード カリストガ エルエルシー | ホスファチジルイノシトール３−キナーゼ阻害剤としての置換ピリミジンアミノアルキル−キナゾロン |
| NZ708870A (en) | 2012-12-21 | 2016-09-30 | Gilead Calistoga Llc | Isoquinolinone or quinazolinone phosphatidylinositol 3-kinase inhibitors |
| TWI527811B (zh) | 2013-05-09 | 2016-04-01 | 吉李德科學股份有限公司 | 作爲溴結構域抑制劑的苯並咪唑衍生物 |
| NZ714710A (en) | 2013-06-14 | 2016-11-25 | Gilead Sciences Inc | Phosphatidylinositol 3-kinase inhibitors |
| AU2014296308C1 (en) | 2013-07-30 | 2018-09-13 | Kronos Bio, Inc. | Polymorph of Syk inhibitors |
| US9290505B2 (en) | 2013-12-23 | 2016-03-22 | Gilead Sciences, Inc. | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors |
| TWI662037B (zh) | 2013-12-23 | 2019-06-11 | 美商基利科學股份有限公司 | 脾酪胺酸激酶抑制劑 |
| CN106456602B (zh) * | 2014-03-27 | 2020-11-24 | 范德比尔特大学 | 取代的吲哚mcl-1抑制剂 |
| US10611837B2 (en) | 2014-04-10 | 2020-04-07 | Seattle Children's Hospital | Transgene genetic tags and methods of use |
| TWI751102B (zh) | 2014-08-28 | 2022-01-01 | 美商奇諾治療有限公司 | 對ｃｄ１９具專一性之抗體及嵌合抗原受體 |
| EP3517536B1 (en) | 2014-09-26 | 2021-05-05 | Gilead Sciences, Inc. | Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds |
| KR102804498B1 (ko) | 2014-12-03 | 2025-05-08 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 세포 치료를 위한 방법 및 조성물 |
| CA2966234A1 (en) | 2014-12-15 | 2016-06-23 | Bellicum Pharmaceuticals, Inc. | Methods for controlled elimination of therapeutic cells |
| EA201792259A1 (ru) | 2015-05-15 | 2018-06-29 | Джилид Сайэнс, Инк. | Бензимидазольные и имидазопиридиновые карбоксимидамидные соединения |
| AU2016271147B2 (en) | 2015-05-29 | 2022-09-08 | Juno Therapeutics, Inc. | Composition and methods for regulating inhibitory interactions in genetically engineered cells |
| IL297003A (en) | 2015-09-17 | 2022-12-01 | Novartis Ag | car-t cell treatments with improved efficacy |
| JP6453507B2 (ja) | 2017-03-30 | 2019-01-16 | アムジエン・インコーポレーテツド | Ｍｃｌ−１タンパク質を阻害する化合物 |
| ES3036998T3 (en) | 2017-08-18 | 2025-09-26 | Amgen Inc | Compounds that inhibit mcl-1 protein |
| EP3676270A1 (en) | 2017-08-29 | 2020-07-08 | Amgen Inc. | Macrocyclic compounds that inhibit mcl-1 protein |
| AU2018351059B2 (en) | 2017-10-19 | 2022-05-12 | Teijin Pharma Limited | Benzimidazole derivatives and their uses |
| US11274105B2 (en) | 2018-03-05 | 2022-03-15 | Amgen Inc. | Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere Mcl-1 protein antagonists |
| CN112118845B (zh) | 2018-05-14 | 2023-06-13 | 吉利德科学公司 | Mcl-1抑制剂 |
| US11827664B2 (en) | 2018-05-14 | 2023-11-28 | Reata Pharmaceuticals, Inc | Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway |
| KR20210010475A (ko) | 2018-05-15 | 2021-01-27 | 룬드벡 라 졸라 리서치 센터 인코포레이티드 | Magl 저해제 |
| KR20210038911A (ko) | 2018-07-24 | 2021-04-08 | 에피자임, 인코포레이티드 | Smarca2 길항제로서 유용한 피리딘-2-온 화합물 |
| WO2020097577A1 (en) | 2018-11-09 | 2020-05-14 | Prelude Therapeutics, Incorporated | Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein |
| WO2020147802A1 (en) | 2019-01-18 | 2020-07-23 | Ascentage Pharma (Suzhou) Co., Ltd. | Macrocyclic spiroethers as mcl-1 inhibitors |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| AU2020391106B2 (en) | 2019-11-26 | 2024-03-21 | Gilead Sciences, Inc. | Processes and intermediates for preparing MCL1 inhibitors |
| JP2021161114A (ja) | 2020-03-31 | 2021-10-11 | アムジエン・インコーポレーテツド | Ｍｃｌ−１化合物のメチル化 |
| TWI827924B (zh) | 2020-05-06 | 2024-01-01 | 美商安進公司 | 大環Mcl-1抑制劑中間體的閉環合成 |
| AU2021268569B2 (en) | 2020-05-06 | 2024-06-13 | Amgen Inc. | Synthesis of vinylic protected alcohol intermediates |
| CN115698023A (zh) | 2020-06-10 | 2023-02-03 | 詹森药业有限公司 | 作为mcl-1抑制剂的大环2-氨基-3-氟-丁-3-烯酰胺 |
| JP2023532592A (ja) | 2020-07-08 | 2023-07-28 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍｃｌ－１の阻害剤としての大環状エーテル含有インドール誘導体 |
| US12202782B2 (en) | 2020-11-19 | 2025-01-21 | Gilead Sciences, Inc. | Processes and intermediates for preparing MCL1 inhibitors |
-
2019
- 2019-05-13 CN CN201980032695.2A patent/CN112118845B/zh active Active
- 2019-05-13 HU HUE19728793A patent/HUE057852T2/hu unknown
- 2019-05-13 HR HRP20220215TT patent/HRP20220215T1/hr unknown
- 2019-05-13 AU AU2019269391A patent/AU2019269391B2/en active Active
- 2019-05-13 PT PT197287931T patent/PT3793565T/pt unknown
- 2019-05-13 KR KR1020237022152A patent/KR102666717B1/ko active Active
- 2019-05-13 MX MX2020012137A patent/MX2020012137A/es unknown
- 2019-05-13 US US16/410,457 patent/US10703733B2/en active Active
- 2019-05-13 SG SG11202010964VA patent/SG11202010964VA/en unknown
- 2019-05-13 PL PL19728793T patent/PL3793565T3/pl unknown
- 2019-05-13 WO PCT/US2019/032053 patent/WO2019222112A1/en not_active Ceased
- 2019-05-13 CR CR20200544A patent/CR20200544A/es unknown
- 2019-05-13 SI SI201930181T patent/SI3793565T1/sl unknown
- 2019-05-13 CA CA3099152A patent/CA3099152C/en active Active
- 2019-05-13 KR KR1020247015778A patent/KR102732008B1/ko active Active
- 2019-05-13 JP JP2020564228A patent/JP6899975B2/ja active Active
- 2019-05-13 LT LTEPPCT/US2019/032053T patent/LT3793565T/lt unknown
- 2019-05-13 ES ES19728793T patent/ES2907923T3/es active Active
- 2019-05-13 IL IL291430A patent/IL291430B2/en unknown
- 2019-05-13 MY MYPI2020005671A patent/MY198871A/en unknown
- 2019-05-13 UA UAA202006695A patent/UA125163C2/uk unknown
- 2019-05-13 PE PE2020001829A patent/PE20210004A1/es unknown
- 2019-05-13 DK DK19728793.1T patent/DK3793565T3/da active
- 2019-05-13 KR KR1020247038029A patent/KR20240165483A/ko active Pending
- 2019-05-13 KR KR1020207035485A patent/KR102551319B1/ko active Active
- 2019-05-13 EP EP21218221.6A patent/EP4029868A1/en active Pending
- 2019-05-13 BR BR112020021648-8A patent/BR112020021648A2/pt unknown
- 2019-05-13 EP EP19728793.1A patent/EP3793565B1/en active Active
- 2019-05-13 CN CN202310897123.9A patent/CN117304130A/zh active Pending
- 2019-05-14 TW TW108116508A patent/TWI719478B/zh active
- 2019-05-14 TW TW110107128A patent/TWI813957B/zh active
- 2019-05-14 TW TW113116186A patent/TW202506687A/zh unknown
- 2019-05-14 TW TW112131732A patent/TWI844454B/zh active
-
2020
- 2020-04-23 US US16/857,021 patent/US10988451B2/en active Active
- 2020-10-27 IL IL278336A patent/IL278336B/en unknown
- 2020-11-03 PH PH12020551881A patent/PH12020551881A1/en unknown
- 2020-11-10 ZA ZA2020/07007A patent/ZA202007007B/en unknown
- 2020-11-10 CO CONC2020/0014009A patent/CO2020014009A2/es unknown
- 2020-11-10 CL CL2020002919A patent/CL2020002919A1/es unknown
-
2021
- 2021-02-09 US US17/171,201 patent/US11643400B2/en active Active
- 2021-03-09 JP JP2021037000A patent/JP7240431B2/ja active Active
- 2021-05-25 AU AU2021203373A patent/AU2021203373B2/en active Active
-
2022
- 2022-03-16 CY CY20221100208T patent/CY1125065T1/el unknown
-
2023
- 2023-03-03 JP JP2023032872A patent/JP2023060145A/ja active Pending
- 2023-03-09 US US18/181,336 patent/US12162844B2/en active Active
- 2023-11-24 AU AU2023270332A patent/AU2023270332B2/en active Active
-
2024
- 2024-10-17 US US18/918,629 patent/US20250154116A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016033486A1 (en) * | 2014-08-29 | 2016-03-03 | Amgen Inc. | Tetrahydronaphthalene derivatives that inhibit mcl-1 protein |
| WO2017147410A1 (en) * | 2016-02-25 | 2017-08-31 | Amgen Inc. | Compounds that inhibit mcl-1 protein |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021203373B2 (en) | MCL-1 inhibitors | |
| JP7792036B2 (ja) | Ｍｃｌ－１阻害剤 | |
| HK40078700A (en) | Mcl-1 inhibitors | |
| HK40048157B (en) | Mcl-1 inhibitors | |
| HK40048157A (en) | Mcl-1 inhibitors | |
| EA043742B1 (ru) | Ингибиторы mcl-1 | |
| HK40038496B (en) | Mcl-1 inhibitors | |
| HK40038496A (en) | Mcl-1 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |